You are here

Our science / Clinical Trials / Find a Trial / NCT00618007

Effect of PF-00734200 in Subjects With Type 2 Diabetes

Back to Search Print Save as PDF Bookmark Trial

NCT00618007

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Birmingham, Alabama, 35205 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Men or women between 18-80 years of age with poorly controlled Type 2 diabetes

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Type 1 or secondary forms of diabetes Currently using insulin

NCT00618007
Pfizer
Completed
Effect of PF-00734200 in Subjects With Type 2 Diabetes

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Ovarian Cancer HR+ HER2- Metastatic Breast Cancer
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
NCT03519178
All Genders
18+
Years
Multiple Sites
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
NCT02573259
All Genders
18+
Years
Multiple Sites
Type 2 Diabetes Mellitus
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
NCT00367445
All Genders
18+
Years
Chula Vista, California
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
NCT00138671
All Genders
30+
Years
Multiple Sites
Effect of PF-00734200 in Subjects With Type 2 Diabetes
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of 12-Week Administration Of PF-00734200 To Subjects With Type 2 Diabetes Mellitus And Insufficient Glycemic Control On Metformin Treatment
To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: PF-00734200 30 mg QD
    30 mg QD
  • Drug: PF-00734200 20 mg QD
    20 mg QD
  • Drug: Placebo
    Placebo
  • Experimental: 30 mg QD
    Intervention: Drug: PF-00734200 30 mg QD
  • Experimental: 20 mg QD
    Intervention: Drug: PF-00734200 20 mg QD
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
289
August 2008
August 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Men or women between 18-80 years of age with poorly controlled Type 2 diabetes

Exclusion Criteria:

Type 1 or secondary forms of diabetes Currently using insulin
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Korea, Republic of,   Puerto Rico,   United States
 
 
NCT00618007
A7941006
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now